AndroBioSys, Inc. (ABS), is a biotechnology company dedicated to the development of novel treatments for prostate disease. Based on technologies developed at Roswell Park Cancer Institute, AndroBioSys is pioneering new approaches to make treatment of prostate cancer curative, not palliative. Preventing progression of prostate disease is intertwined intimately with disruption of the androgen axis. ABS performs contract research screening services for academic, biotechnology and pharmaceutical clients and develops collaborative partnerships to discover new drugs to proprietary prostate disease targets
